Related Experiment Video
Updated: Apr 7, 2026
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.5K
A clinically applicable molecular-based classification for endometrial cancers.
A Talhouk1, M K McConechy1, S Leung2
1Department of Pathology and Laboratory Medicine, University of British Columbia and BC Cancer Agency, 509-2660 Oak Street, Vancouver, British Columbia, Canada V6H 3Z6.
British Journal of Cancer
|July 15, 2015
Summary
A new molecular classification for endometrial carcinoma (EC) using accessible assays provides independent prognostic information. This method refines risk stratification beyond traditional clinical factors for improved treatment guidance.
Area of Science:
- Gynecologic Oncology
- Molecular Pathology
- Cancer Genomics
Background:
- Current morphologic classification of endometrial carcinomas (ECs) lacks prognostic and predictive accuracy.
- The Cancer Genome Atlas (TCGA) identified molecular subtypes of ECs with distinct prognoses.
- A need exists for clinically applicable molecular classification of ECs.
Purpose of the Study:
- To develop and validate surrogate molecular assays for EC classification based on TCGA findings.
- To compare molecular classification with traditional clinical risk stratification.
- To assess the prognostic value of a novel molecular classifier for EC.
Main Methods:
- Utilized TCGA genomic data to identify key molecular drivers for EC classification.
- Developed surrogate assays including mismatch repair protein IHC, POLE mutation analysis, and p53 IHC.
- Validated the molecular classifier on an independent cohort of 152 EC cases, comparing it with clinical risk groups.
Main Results:
- Multiple molecular classification models successfully replicated TCGA survival curves.
- The validated classifier, using mismatch repair protein IHC, POLE mutation analysis, and p53 IHC, showed significant association with clinical outcomes.
- Molecular classification provided independent prognostic information, differing in risk group composition compared to clinical stratification.
- Combining molecular and clinicopathologic features yielded the highest accuracy in predicting patient outcomes.
Conclusions:
- Clinically applicable molecular classification of ECs is feasible using formalin-fixed paraffin-embedded samples.
- This molecular approach offers independent prognostic value beyond established risk factors.
- The developed classification tool can guide individual treatment decisions and stratify patients for clinical trials.
